Maximizing the potential of each and every asset we develop is a critical need for the pharma industry, recognising the value of efficient and effective investment in the right programs at the right time. However, to fully realise the true lifecycle value for an asset, teams need to consider an appropriate balance of both short-term goals and long-term strategy across a set of key lifecycle decision points. In this infographic, we highlight the six strategic decision points and key associated workstreams to consider for planning to create robust strategic plans for future success.
Early Lifecycle Management
Strategic Decision Point 1: Foundational Strategy Setting
Priorities in Preclinical and Phase I/II
Identify the optimal launch indication(s) that will maximize probability of success and commercial potential at launch and through the product lifecycle.
Associated Workstreams:
- MoA to indication mapping
- Broad indication assessment
- Prioritization and initial LCM mapping
Strategic Decision Point 2: Full Profile Mapping
Priorities in Phase II/ Phase III
Support optimization of first launch indications while charting the best course for brand expansion into areas of unmet patient need and competitive value.
Associated Workstreams:
- Launch indication gap analysis
- Integrated evidence strategy build
- Adjacency mapping and prioritization
Strategic Decision Point 3: Post Launch Optimization
Priorities from 2 years post-launch
Drive post-launch optimization of the product profile by addressing unmet patient needs, new competitive threats, and refining value propositions based on post-launch learnings.
Associated Workstreams:
- Core indication optimization
- Full indication range prioritization
- Solution strategy optimization
Late Lifecycle Management
Strategic Decision Point 4: Long-range LLC Preparation
Priorities from 6-7 years pre-LoE
Build and reinforcecompetitive value forpatients and payers, while delivering sustainable commercial value.
Associated Workstreams:
- LLC situation analysis and scenario planning
- Long-range LLC tactic ideation and prioritization
Strategic Decision Point 5: Near-Term LLC Preparation
Priorities from 3 years pre-LoE
Focus on near-term LLC planning where local teams need to prepare to compete and reinforce competitive value as they transition into a post-LOE environment.
Associated Workstreams:
- LLC market archetype development and mapping
- Local LLC plan development and execution
Strategic Decision Point 6: Established Brand Optimization
Priorities from 2 years post-LoE
Focus on optimizing the patient and/payer value ofthe molecule in the post-LOE environment.
Associated Workstreams:
- Mapping of post-LoE opportunities
- Growth market strategy support
- Established brand portfolio management
